Anaphylaxis

In this quiz, we test your knowledge of evidence-based management strategies, recommended epinephrine doses, and evolving guidance on patient follow-up and discharge planning for anaphylaxis.

A study found 1 in 7 children with anaphylaxis experience biphasic reactions after epinephrine, with no recurrences after 4 hours, highlighting corticosteroid impact.

Children with urticaria or angioedema face greater risks of adverse events after COVID-19 vaccination, but most tolerate subsequent doses with proper management.

Data from the CAFETERIA trial provide insight into exposure vs avoidance strategies for high-threshold peanut allergy.

An analysis found anaphylaxis following non-COVID vaccines is rare, with greater rates for yellow fever and influenza vaccines.

Test your knowledge of the 2023 Anaphylaxis Update from the Joint Task Force on Practice Parameters, focusing on diagnoses and biomarkers!

Needle-free treatments, such as Neffy and FluMist, offer promising alternatives for children and adults with needle phobia, ensuring access to critical care.

The FDA affirmed the planned NDA content and format for Anaphylm expected in Q1 2025, without requiring additional adult clinical trials before submission.

These data were explored to identify risk, recommendations, and guidelines related to vaccine-related allergic reactions such as anaphylaxis.

In recent findings presented at ACAAI 2024, patients, caregivers, and even emergency medical professionals were shown to face issues with regard to treatment of anaphylaxis reactions.

The Parental Self-efficacy in Managing Anaphylaxis (PSEMA) questionnaire was shown to be effective in assessing self-efficacy of parents in managing their childrens’ conditions.

Aquestive Therapeutics plans to submit an NDA for Anaphylm in Q1 2025 based on topline results from the Oral Allergy Syndrome challenge study.

Early epinephrine intervention at home can potentially successfully treat anaphylaxis in children without further treatment in a hospital setting.

During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such reactions.

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

The announcement follows July’s approval of the nasal spray, also known as neffy, for patients with Type 1 allergic reactions such as anaphylaxis.

These new data were announced by Aquestive Therapeutics and if approved, Anaphylm Sublingual Film could be the first orally-delivered, non-invasive severe allergy treatment.

In an announcement by Aquestive Therapeutics, these new findings demonstrated the potential of this orally-administered epinephrine treatment.

These findings may allow for patients with severe allergic reactions to have an alternative to epinephrine auto-injector devices.

These results provided valuable insights into occupational anaphylaxis through the use of anaphylaxis registry data.

The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.

These newly-updated parameters were a response by the ACAAI and the AAAAI to recent evidence that had become visible.

The FDA's announcement requesting further study represents a step back in the process of 'neffy' becoming the first needle-free nasal spray epinephrine alternative.

This new research examined trends among adults with severe and recurrent anaphylaxis, and identified several major risk factors.

In phase 3 data presented at the AAAAI conference, an investigational intranasal epinephrine spray was found to have higher and more sustained pharmacokinetics than the standard reference product.

French researchers find that targeted allergy assessments may be needed in children with peanut allergies.

Dr. Epstein provides updates on a joint study between members of AAAAI and the American College of Allergy on the relationship between epinephrine and post-immunotherapy injection waiting periods.

Urticaria and angioedema with oral mucocutaneous involvement were commonly labeled as anaphylaxis upon presentation.

The proportion of anaphylaxis episodes was higher in the cohort of patients with peanut allergies, compared to a control group of patients with non-peanut food allergies.

Data pooled from 5 trials show a consistent and manageable safety profile for continued treatment with PALFORZIA.